Ana Villar

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 559 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12

Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study

Ferrán Morell, Ana Villar, María-Ángeles Montero et al. · The Lancet Respiratory Medicine · 2013 · 388 citations

Medicine, Internal Medicine, Pathology +16

Diagnosis and Evaluation of Hypersensitivity Pneumonitis

Evans R. Fernández Pérez, William D. Travis, David A. Lynch et al. · CHEST Journal · 2021 · 243 citations · Full text

Life Sciences, Immunology, Internal Medicine +10

Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven^®) in children vs. adults with haemophilia A

Ana Villar, S Aronis, Massimo Morfini et al. · Haemophilia · 2004 · 148 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +11

Global warming vs. climate change, taxes vs. prices: Does word choice matter?

Ana Villar, Jon A. Krosnick · Climatic Change · 2010 · 130 citations

Social Sciences, Economics, Climate Policy +6